Medicare Part D Premiums in 2027: Why the Headline Numbers Disagree
The Centers for Medicare & Medicaid Services (CMS) says the Part D base beneficiary premium will be $41.33 per month in 2027, up from $38.99 in 2026. Part D is Medicare's prescription drug coverage. The CMS fact sheet, published July 28, 2026, also sets the calendar year 2027 national average monthly bid amount at $296.05 and announces the conclusion of the Part D Premium Stabilization Demonstration.
The base beneficiary premium is the standard monthly benchmark that anchors Part D premium calculations. Think of it as a reference price that individual plan premiums are measured against. The $2.34 increase works out to about 6.0%. That is a single, program-wide number, and it does not tell a given enrollee what they will pay.
A far larger figure is in circulation. A Healthcare Dive report published November 2, 2026 projects average monthly Part D premiums will jump 50%, from $34 to $51, in 2027, assuming seniors stay on their current plans.
The gap between a 6% benchmark move and a 50% average projection is the first thing an analyst should work through. In my view, most of that gap is about measurement, not contradiction. The average projection tracks what enrollees actually pay, and it depends heavily on the plan-switching assumption.
CMS offered a different read earlier in the cycle. In a September 28, 2026 press release, the agency projected that the average premium for stand-alone Part D prescription drug plans would rise by less than $1 per month in 2027.
Readers comparing the two should check the denominators, the plan types, and the enrollment base each figure uses before drawing a conclusion about the direction of premiums.
On the Medicare Advantage side, Reuters reported on September 29, 2026 that CMS projects Medicare Advantage premiums will fall by more than 16% in 2027. Medicare Advantage is the privately run alternative to original Medicare. Payments to those plans are a separate matter. The April 6, 2026 rate announcement fact sheet says final policies are projected to raise payments to Medicare Advantage plans by 2.48%, or over $13 billion.
A premium decline for enrollees alongside a payment increase to plans is not a contradiction on its face. The two numbers come from different mechanisms and should be modeled separately.
The annual out-of-pocket cap on Part D drug spending rises to $2,400 in 2027, up from $2,100 in 2026, according to a PBS NewsHour report published October 15, 2026. That is an increase of about 14.3%. The cap is the ceiling on a beneficiary's annual out-of-pocket drug costs.
For high-cost enrollees, this is probably the figure that matters most. A higher ceiling means more possible annual spending, even as the monthly premium moves in a different direction.
Medicare Open Enrollment runs from October 15 to December 7 each year, so the current window closes in about five weeks. During this window beneficiaries can change plans. Anyone who keeps the same plan under the same benefit design will see the premium they are quoted for 2027. Anyone comparing options has to look at plan-level figures rather than program averages.
That is why the 50% projection's assumption that seniors stay put matters so much. If enrollees switch in large numbers, the average paid premium would look very different.
For most enrollees, the program-wide numbers answer the question of direction but not the question of cost. The base premium rose about 6%. The average projected premium is pegged at a far larger increase. The out-of-pocket cap rose about 14%. The enrollee's own plan documents, not the national averages, will determine the bill.
